Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

ARE · Q3 2025 Earnings

Alexandria Real Estate Equities

Reported October 27, 2025

30-second summary

30-second take: Alexandria cut FY2025 FFO/share guidance ~2.4% at the midpoint (to $8.98–$9.04 from $9.16–$9.36), narrowed and lowered year-end occupancy to 90.0%–91.6%, and raised the leverage band to 5.5–6.0x — above the prior ≤5.2x ceiling — with Q3 already at 6.1x. Management withdrew GAAP EPS guidance, withdrew the $1.45–$2.45B disposition guide, and explicitly committed to shrinking the development pipeline from 20% toward 10–15% of assets, with the dividend now under board review with "room potentially up to 30%, 40%" downside. This is no longer a cyclical-trough story; it is a balance-sheet defense story.

Headline numbers

EPS

Q3 FY2025

$2.22

Revenue

Q3 FY2025

$0.75B

-4.9% YoY

Operating margin

Q3 FY2025

68.0%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$0.75B	-4.9%	$0.76B	-1.3%
EPS	$2.22	—	$2.33	-4.7%
Operating margin	68.0%	—	71.0%	-300bps

Guidance

Broad FY2025 guidance cuts across FFO, occupancy, NOI, and leverage; company narrowed focus to adjusted metrics while withdrawing GAAP and cash-basis disclosures, signaling material portfolio deterioration and debt concerns.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
FFO per share, as adjusted	FY 2025	$9.16 to $9.36	$8.98 to $9.04	-$0.12 to -$0.32 (midpoint -$0.22)	Lowered
Operating occupancy percentage in North America	FY 2025	90.9% to 92.5%	90.0% to 91.6%	-0.9 to -0.9 percentage points (range narrowed, midpoint down ~0.7pts)	Lowered
Same property NOI change	FY 2025	(3.7)% to (1.7)%	(4.7)% to (2.7)%	-1.0 percentage points at both ends	Lowered
Lease renewal rental rate changes	FY 2025	9.0% to 17.0%	7.0% to 15.0%	-2.0 percentage points at both ends	Lowered
Fixed-charge coverage ratio	FY 2025	4.0x to 4.5x	3.6x to 4.1x	-0.4x at both ends	Lowered
Net debt and preferred stock to Adjusted EBITDA	FY 2025	≤5.2x	5.5x to 6.0x	+0.3 to +0.8x (from prior ≤5.2x cap)	Lowered
GAAP earnings per share	FY 2025	$0.40 to $0.60	Withdrawn — no replacement	—	Withdrawn
Dispositions and sales of partial interests	FY 2025	$1,450 million to $2,450 million	Withdrawn — no replacement	—	Withdrawn
Same property NOI change (cash basis)	FY 2025	(1.2)% to 0.8%	Withdrawn — no replacement	—	Withdrawn
Lease renewal rental rate changes (cash basis)	FY 2025	0.5% to 8.5%	Withdrawn — no replacement	—	Withdrawn

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Operating Occupancy	90.6%
Operating Occupancy including leased but not yet delivered	92.2%
Megacampus Platform % of Annual Rental Revenue	77%
Investment-grade or publicly traded large cap tenants % of revenue	53%
Leasing Volume	1,171,344 RSF
Rental Rate Increase on Renewals and Re-leasing	15.2% (6.1% cash basis)
Adjusted EBITDA Margin	71%
Net Debt and Preferred Stock to Adjusted EBITDA	6.1x

Management tone

Q2 anchor: "industry bottoming" → Q3 anchor: "wheels are substantially stopped"

From bottoming to indefinite trough. Last quarter management framed the cycle with "we kind of have been bottoming"; this quarter Joel said the "wheels are substantially stopped" and explicitly listed prerequisites for recovery — FDA reopening, venture capital, IPO market, lower cost of capital — without committing to a timeline. The opening line of the call — "Our team continues to navigate a challenging environment given macro industry and policy factors beyond our control" — sets a defensive frame and explicitly disclaims control. Three quarters ago ARE was positioning megacampus brand equity as a demand magnet; this quarter the brand is positioned as a defensive moat against deteriorating sector fundamentals.

From "review 2027 redevelopment for lower-cost options" to "shrink the development pipeline by half." Q2 introduced the idea of cost re-evaluation on 2027 projects. This quarter the language hardened into a structural target: "we curtail our large development pipeline coming off a decade bull run for the industry fueled by the rocket ship demand of COVID...we're carefully evaluating on a project by project basis the 4.2 billion of land subject to capitalization." The 20%-to-10–15% pipeline contraction is a multi-year strategic pivot, not a tactical pause. Management is acknowledging it overbuilt into a peak.

From dispositions as the leverage solution to dispositions as optional. Q2 disclosed a $1.45–$2.45B disposition guide as the explicit bridge from 5.9x to ≤5.2x leverage. This quarter that guide is withdrawn entirely, replaced by qualitative ranges of "$0 to $685M of potential impairments" and "$0 to $240M of potential gains" — language that signals the asset sale market is unclear enough that committing to a number is no longer prudent. That is a meaningful loss of forward visibility.

From dividend correlation with FFO to dividend under review. Q2 maintained the historical dividend-FFO correlation framework. This quarter: "the board will look at that in the fourth quarter...the board will obviously make the final decision, but there's room potentially up to 30%, 40%" on payout. That is conditional language replacing what was effectively a commitment. Dividend cut risk has moved from tail to base case.

From "macro persists" to "macro is the operating model." Two quarters ago FDA/NIH/tariffs were headwinds; this quarter government shutdown and FDA closure are framed as live operational blockers to tenant decision-making. The hedging vocabulary expanded — "given the lack of clarity on near-term demand," "although these potential impairments have not been triggered" — suggesting management lacks line-of-sight on Q4, let alone 2026.

Recurring themes management leaned on this quarter:

Government shutdown and FDA closure as near-term demand blockersSupply oversupply in select submarkets driving occupancy declinesMega campus portfolio outperformance but offset by non-core asset underperformanceBalance sheet deleveraging through aggressive non-core asset and land salesDevelopment pipeline contraction from 30% to 10-15% of portfolioTenant capital constraints extending decision timelines despite positive XBI sentiment

Risks management surfaced:

Regulatory environment: FDA closure, government shutdown impacting drug approvals and clinical trialsVenture capital market: Five-year bear market limiting tenant funding and expansionIPO market closure limiting biotech capital formationOversupply in certain submarkets (especially non-mega campus assets)Potential for further impairments on $0-685M of assets under consideration for saleInterest capitalization rolloff creating earnings headwinds as development pipeline paused

Answers to last quarter's watch list

Occupancy stabilization vs. the 90.9%–92.5% year-end band. Breached, decisively. Q3 occupancy printed 90.6% (down 20bps QoQ from 90.8%), and management cut the year-end band to 90.0%–91.6%. The recovery thesis is gone. Status: Resolved negatively

Disposition execution against the $1.45B–$2.45B FY guide. The entire disposition guide was withdrawn. There is no longer a forward number to measure against; in its place, management offered qualitative ranges of $0–$685M of potential impairments and $0–$240M of potential gains for 4Q25 or 2026. Status: Resolved negatively

Same-property NOI trajectory within the (3.7)% to (1.7)% guide. The band was cut by 100bps at both ends to (4.7)%–(2.7)%, confirming the low-end-of-prior-band concern and then some. The cash-basis NOI guide was withdrawn entirely, eliminating the cleanest read on underlying operations. Status: Resolved negatively

Concrete decisions on 2027 redevelopment re-evaluation. Management escalated from project-level review to a structural pipeline target of 10–15% of assets (down from ~20% currently, down from 30% historically), with $4.2B of capitalized land basis being evaluated project-by-project for pause/curtailment. Specific projects weren't named, but the framework is now explicit. Status: Resolved negatively

Lease renewal rate spreads holding +9%–+17% (GAAP) and +0.5%–+8.5% (cash). Q3 actuals beat (+15.2% GAAP, +6.1% cash), but the FY guide was cut 200bps to +7.0%–+15.0% GAAP, and the cash-basis guide was withdrawn entirely. The withdrawal is more telling than the in-quarter beat — management no longer wants to commit to cash-basis pricing visibility. Status: Resolved negatively

What to watch into next quarter

Whether Q4 leverage lands inside the new 5.5x–6.0x band from a 6.1x starting point. With dispositions de-guided and EBITDA under pressure, a Q4 print at or above 6.0x would suggest the new band is already stale and 2026 financing risk is live.

Dividend decision at the Q4 board meeting. Management telegraphed "room potentially up to 30%, 40%" on payout. Watch for the absolute per-share level and the framing — a cut anchored to 2026 FFO would be a multi-year reset, not a one-quarter adjustment.

Quantified impairments and gain-on-sale execution within the $0–$685M / $0–$240M qualitative ranges. A heavy impairment print would compress book value; a heavy gain-on-sale print would validate the still-functioning private-market bid for megacampus assets.

Specific project pauses or cancellations from the $4.2B capitalized land basis. Watch for capitalized interest disclosure changes in the Q4 supplemental — that is where deferrals show up first, and it telegraphs the magnitude of the 2026 earnings headwind.

2026 FFO/share commentary on the Q4 call. Q3 already flagged "factors expected to impact 2026 earnings and cash flows." The first 2026 guide framing — whether it acknowledges another step-down or projects stabilization — will set the dividend math and the equity story.

Same-property NOI direction inside the new (4.7)%–(2.7)% band. A Q4 print toward the low end would mean the 1.2M sq ft of known 2026 vacates is hitting earlier than modeled.

Sources

Alexandria Real Estate Equities Q3 2025 Earnings Supplemental — https://www.sec.gov/Archives/edgar/data/1035443/000103544325000199/a3q25ex991supp.htm
Alexandria Real Estate Equities Q2 2025 Earnings Supplemental — https://www.sec.gov/Archives/edgar/data/1035443/000103544325000182/a2025ex991supp.htm

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.